The Swedish Research Council has not yet been notified by the government about the budget for the announcement in development research, and the research funder has therefore published a recommendation on which projects will receive funding. Tomas Bergström, Senior Professor of Microbiology, is recommended to receive SEK 3.9 million for his project, which develops a drug candidate against respiratory syncytial virus (RSV), which is the main cause of pneumonia in children. Vaccination does not work against this virus, which kills hundreds of thousands of children annually in developing countries. The project is based on cooperation with expertise in Mozambique, where researchers will cooperate to investigate virus strain viability as part of this drug development.